Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled trial of ZYY-750 for diabetic foot ulcer
CTR20243463Phase 2Active
- Sponsor
- Yangzijiang Pharmaceutical Group
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic foot ulcer (DFU) comparing ZYY-750 with Placebo (2 arms). Primary endpoints: Complete healing rate of the target ulcer, Percent change in target ulcer area from baseline and 7 more. Started Dec 2024; status: active.
02
Drugs
recombinant human acidic fibroblast growth factor
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on CTR20243463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243463.